Production and composition of prothrombin complex concentrates: Correlation between composition and therapeutic efficiency

Thrombosis Research

Volumn 95, Issue 4 SUPPL. 1, 1999, Pages

  Hellstern, Peter ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

Composition; Production; Prothrombin complex concentrates; Therapeutic efficiency

Indexed keywords

PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; BLOOD CLOTTING TIME; CLINICAL TRIAL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DETERMINATION; DRUG FORMULATION; DRUG MANUFACTURE; HUMAN; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; THROMBOEMBOLISM; THROMBOGENICITY;

EID: 0032822039     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00078-X     Document Type: Article

References (41)

1. Mannucci P.M., Franchi F., Dioguard N. Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet. 2:1976;542-545.
2. Makros M., Greaves M., Phillipps W.S., Kitchen S., Rosendaal F.R., Preston F.E. Emergency oral anticoagulant reversal. The relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy Thromb Haemost. 77:1997;477-480.
3. Staudinger T., Locker G.J., Frass M. Management of acquired coagulation disorders in emergency and intensive-care medicine. Sem Thromb Hemost. 22:1996;93-104.
4. Berntorp E. Why prescribe highly purified factor VIII and IX concentrates? Vox Sang. 70:1996;61-68.
5. Hilgartner M., Aledort M., Andes A., Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion. 30:1990;626-630.
6. Lusher J.M. Prediction and management of adverse events associated with the use of factor IX complex concentrates. Sem Hematol. 30(Suppl 1):1993;36-40.
7. Chong B.H. Heparin-induced thrombocytopenia. Br J Haematol. 89:1995;431-439.
8. Feldman P., Winkelman L. Preparation of special plasma products. Harris J.R. Blood Separation and Plasma Fractionation. 1991;341-383 Wiley-Liss, New York.
9. Chandra S., Wickerhauser M. Large scale preparation of nonthrombogenic prothrombin complex. Thromb Res. 12:1978;571-582.
10. Feldman P.A., Evans H., Sims G., Smith J.K. New formulation for BPL factor IX concentrate (9A). Br J Haematol. 73:1989;444.
11. Ménaché D., Roberts H.R. Summary report and recommendations of the Task Force Members and Consultants. Thrombos Diathes Haemorrh. 33:1975;645-647.
12. Human prothrombin complex, freeze-dried. Pharmeuropa 1996;8:29-30.
13. Lusher J.M. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol. 28(Suppl 6):1991;3-5.
14. Kingdon H.S., Lundblad R.L., Veltkamp J.J., Aronson D.L. Potentially thrombogenic materials in factor IX concentrates. Thrombos Diath Haemorrh. 33:1975;617-631.
15. White G.C., Roberts H.R., Kingdon H.S., Lundblad R.L. Prothrombin complex concentrates. Potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo Blood. 49:1977;159-170.
16. Elödi S., Váradi K. Activation of clotting factors in prothrombin complex concentrates as demonstrated by clotting assays for factors IXa and Xa. Thromb Res. 12:1978;797-807.
17. Hultin M.B. Activated clotting factors in factor IX concentrates. Blood. 54:1979;1028-1038.
18. Giles A.R., Johnston M., Hoogendoorn H., Blajchman M., Hirsh J. The thrombogenicity of prothrombin complex concentrates. I. The relationship between in vitro characteristics and in vivo thrombogenicity in rabbits Thromb Res. 17:1980;353-366.
19. Giles A.R., Nesheim M.E., Hoogendoorn H., Tracy P.B., Mann K.G. The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits. Blood. 59:1982;401-407.
20. Magner A., Aronson D.L. Toxicity of factor IX concentrates in mice. Dev Biol Stand. 44:1979;185-188.
21. Ménaché D., Behre H.E., Orthner C.L., Nunez H., Anderson H.D., Triantaphyllopoulos D.C., Kosow D.P. Coagulation factor IX concentrate. Method of preparation and assessment of potential in vivo thrombogenicity in animal experiments Blood. 64:1984;1220-1227.
22. Mannucci P.M., Bauer K.A., Gringeri A., Barzegar S., Bottasso B., Simoni L., Rosenberg R.D. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood. 76:1990;2540-2545.
23. Köhler M., Heiden M., Harbauer G., Miyashita C., Mörsdorf S., Braun B., Ernert P., Wenzel E., Rose S., Pindur G. Comparison of different prothrombin complex concentrates - in vitro and in vivo studies. Thromb Res. 60:1990;63-70.
24. Mannucci P.M., Bauer K.A., Gringeri A., Barzegar S., Santagostino F.C., Tradati F.C., Rosenberg R.D. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. Br J Haematol. 79:1991;606-611.
25. Hellstern P., Köhler M. Prothrombin complex concentrates (PCC) and thromboembolic complications. Ann Hematol. 70(Suppl I):1995;A88.
26. Gray E., Tubbs J., Thomas S., Oates A., Boisclair M., Kemball-Cook G., Barrowcliffe T.W. Measurement of activated factor IX in factor IX concentrates. Correlation with in vivo thrombogenicity Thromb Haemost. 73:1995;675-679.
27. Sas G., Owens R.E., Smith J.P., Middleton S., Cash J.D. In vitro spontaneous thrombin generation in human factor IX concentrates. Br J Haematol. 31:1975;25-35.
28. Cash J.D., Owens R., Dalton R.G., Prescott R.J. Thrombogenicity of factor IX concentrates. In vitro and in vivo (rabbit) studies Vox Sang. 35:1978;105-110.
29. Wildgoose P., Nemerson Y., Hansen L.L., Nielsen F.E., Glazer S., Hedner U. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood. 80:1992;25-28.
30. Morrissey J.H., Macik B.G., Neuenschwander P.F., Comp P.C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 81:1993;734-744.
31. Seligsohn U., Østerud B., Rapaport S.I. Coupled amidolytic assay for factor VII. Its use with a clotting assay to determine the activity state of factor VII Blood. 52:1978;978-988.
32. Hellstern P., Beeck H., Fellhauer A., Fischer A., Faller-Stöckl B. Measurement of factor VII and of activated factor VII in healthy individuals and in prothrombin complex concentrates. Thromb Res. 86:1997;493-504.
33. Hellstern P., Beeck H., Fellhauer A., Fischer A., Faller-Stöckl B., for the PCC Study Group Factor VII and activated factor-VII content of prothrombin complex concentrates. Vox Sang. 73:1997;155-161.
34. Philippou H., Adami A., Lane D.A., MacGregor I.R., Tuddenham E.G.D., Lowe G.D.O., Ludlam C.A. High purity factor IX and prothrombin complex concentrate (PCC). Pharmacokinetics and evidence that factor IXa is the thrombotic trigger in PCC Thromb Haemost. 76:1996;23-28.
35. Seligsohn U., Kasper C.K., Østerud B., Rapaport S.I. Activated factor VII. Presence in factor IX concentrates and persistence in the circulation Blood. 53:1979;828-837.
36. Rapaport S.I., Rao L.U.M. The tissue factor pathway. how it has become a "prima ballerina" [Review] Thromb Haemost. 74:1995;7-17.
37. Petersen L.C., Valentin S., Hedner U. Regulation of the extrinsic pathway system in health and disease. The role of factor VIIa and tissue factor pathway inhibitor Thromb Res. 79:1995;1-47.
38. Heinemann H., Schramm W., Hoffmann P., Lierz P. Multi-organ failure after administration of PPSB in a patient with isolated factor VII deficiency. Anästh Intensivmed. 34:1993;130-133.
39. Macik B.G., Lindley C.M., Lusher J.M., Sawyer W.T., Bloom A.L., Harrison J.F., Baird-Cox K., Birch K., Glazer S., Roberts H.R. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa). Results of a phase I study Blood Coagul Fibrinolysis. 4:1993;521-527.
40. Lusher J.M. Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis. 26(Suppl 1):1996;124-130.
41. Fredriksson K., Norrving B., Strömblad L. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke. 23:1992;972-977.